NCT06760546 - A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 23, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2027

Conditions

Hypothalamic ObesityMultiple Pituitary Hormone Deficiency Genetic FormSepto-Optic DysplasiaOptic Nerve HypoplasiaChildhood-onset Combined Pituitary Hormone DeficiencyPituitary Stalk Interruption Syndrome

Interventions

DRUG

Setmelanotide

Solution for daily subcutaneous injection

DRUG

Placebo

Placebo matched to setmelanotide for daily subcutaneous injection

Trial Locations (8)

10032

RECRUITING

Columbia University Irving Medical Center, New York

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

35233

RECRUITING

University of Alabama, Birmingham

55102

RECRUITING

Children's Minnesota, Saint Paul

60611

RECRUITING

Lurie Children's Hospital, Chicago

98105

RECRUITING

Seattle Children's Research Institute, Seattle

02115

RECRUITING

Boston Children's Hospital, Boston

HU32RW

RECRUITING

Hull Royal Infirmary, Hull

All Listed Sponsors

lead

Rhythm Pharmaceuticals, Inc.

INDUSTRY